UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): December 23, 2003
AMERICAN VANGUARD CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 0-6354 | 95-2588080 | ||
| (State or other jurisdiction of incorporation) | Commission File Number | (I.R.S. Employer Identification No.) |
4695 MacArthur Court
Newport Beach, California 92660
(Address of principal executive offices)
Registrant’s telephone number: (949) 260-1200
| Item 5. | Other Events. |
On December 23, 2003, American Vanguard announced that AMVAC Chemical Corporation, a wholly owned subsidiary of the Company, completed the acquisition of certain assets related to the active ingredient dichlorvos (“DDVP”) used in the animal health business and marketed primarily under the trade name Nuvan from Novartis Animal Health, Inc., a business unit of Novarits AG. All more particularly described in Exhibit 99.1.
| Item 7. | Exhibits. |
| 99.1 | Press release issued December 23, 2003 | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERICAN VANGUARD CORPORATION (Registrant) | ||
| By: | /s/ James A. Barry | |
| James A. Barry Senior Vice President Chief Financial Officer | ||
Date: December 23, 2003
3
INDEX TO EXHIBITS
| Exhibit No. |
Description | |
| 99.1 | Press release dated December 23, 2003, of American Vanguard Corporation. | |
4